Cytokinetics' CK-586 Advances After Phase 1 Results, Phase 2 Trial Set for Late 2024
Cytokinetics' CK-586 Advances After Phase 1 Results, Phase 2 Trial Set for Late 2024
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology (ACCP) Annual Meeting in Bethesda, MD. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple oral doses of CK-586. The data support the advancement of CK-586 to a Phase 2 clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which is expected to begin in Q4 2024. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of patients with symptomatic HFpEF with hypercontractility and ventricular hypertrophy.
Cytokinetics, Incorporated（納斯達克股票代碼：CYTK）今天宣佈，在馬里蘭州貝塞斯達舉行的美國臨床藥理學會（ACCP）年會的海報發佈會上，公佈了Ck-4021586（Ck-586）1期研究的數據。該研究實現了評估單劑量和多劑量口服Ck-586的安全性、耐受性和藥代動力學（PK）的主要和次要目標。這些數據支持將Ck-586推進到針對心力衰竭患者的2期臨床試驗，該試驗預計將於2024年第四季度開始，射血分數保持不變（HfPef）。Ck-586 是一種心肌球蛋白抑制劑，正在開發中，可能用於治療一組伴有過度收縮和心室肥大的症狀 HfpEF 患者。
譯文內容由第三人軟體翻譯。